A Comparative Effectiveness Study Evaluating OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl), and Placebo for the Treatment of Attention Deficit Hyperactivity Disorder in Children
Information source: Alza Corporation, DE, USA
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Attention Deficit Hyperactivity Disorder
Intervention: Ritalin (Drug); OROS Methylphenidate HCl (Drug); Placebo (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Alza Corporation, DE, USA Official(s) and/or principal investigator(s): Alza Corporation Clinical Trial, Study Director, Affiliation: ALZA
Summary
The purpose of this study is to compare the effectiveness (onset of effect, time to loss of
effect, and overall efficacy) of methylphenidate given as an OROS® (methylphenidate HCl)
formulation, compared to immediate-release Ritalin® and placebo for the treatment of
Attention Deficit Hyperactivity Disorder (ADHD) in children using standardized attention and
behavior scales, and other assessments. Both OROS® Methylphenidate HCl and Ritalin®
contain the central nervous system stimulant, methylphenidate HCl.
Clinical Details
Official title: Comparative Crossover Study of OROS (Methylphenidate HCl), Ritalin, and Placebo in Children With ADHD
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Primary outcome: IOWA Conners Inattention/Overactivity subscale ratings by the Community School Teacher on Days 6, 13 and 20, evaluating study days 2 - 6, 9 - 13, and 16 - 20, respectively.
Secondary outcome: IOWA Conners Inattention/Overactivity and Oppositional/Defiance subscale ratings; SKAMP attention and deportment ratings; Global assessments; Accuracy and completion on assigned academic tasks; Peer interactions ratings; Incidence of adverse events
Detailed description:
Attention Deficit Hyperactivity Disorder (ADHD) represents the most common neurobehavioral
disorder in children, affecting 3% to 5% of the school-age population. This is a
double-blind, double-dummy, randomized, placebo-controlled, active-controlled, crossover
trial in children with ADHD, to compare the safety and effectiveness (onset of effect, time
to loss of effect and overall efficacy) of OROS® Methylphenidate HCl with standard
immediate-release Ritalin® and placebo. During this study, patients receive each of the
three treatments (OROS® Methylphenidate HCl 18, 36 or 54 milligrams per day, Ritalin® 5, 10
or 15 milligrams three times per day, or placebo) for 7 days, and are assigned to one of
three dosage levels depending upon their prestudy methylphenidate dose and regimen. The
total study participation for each patient will be 21 days. Since ADHD is manifested in a
variety of settings and can affect attention and behavior, this study assesses efficacy in
home, community school, and laboratory school settings using numerous assessments designed
to evaluate various aspects of the disorder. These assessments are completed by a variety
of raters, including the parents/caregivers, community school teachers, laboratory school
teachers and the laboratory school counselor. The primary measure of effectiveness is the
community school teacher's rating on the IOWA Conners Inattention/Overactivity subscale.
Additional measures of effectiveness include IOWA Conners (Inattention/Overactivity and
Oppositional/Defiance subscale) ratings, SKAMP attention and deportment ratings, peer
interaction and other behavioral ratings, global assessments, accuracy and productivity of
independent assigned academic seatwork, and assessments of positive and negative social
behaviors, classroom rule violations and disruptive behaviors. Safety evaluations include
the incidence of adverse events, vital signs, sleep quality, appetite, and the
presence/severity of tics (hard-to-control, repeated twitching of any parts of the body or
hard-to-control repeating of sounds or words). Patients will be given oral doses of: OROS®
(methylphenidate HCl) either 1, 2 or 3 of the 18 milligram tablets once daily, Ritalin® 5,
10, or 15 mg (encapsulated/single capsule) three times per day, or placebo. There are three
treatment groups, each group dosing for 7 days for a total of 21 days on study.
Eligibility
Minimum age: 6 Years.
Maximum age: 12 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients with a diagnosis of one of the three subtypes of Attention Deficit
Hyperactivity Disorder (ADHD) verified by both a parent/child interview and a teacher
assessment using SNAP-IV questionnaires
- taking 5 - 20 mg of immediate-release methylphenidate (Ritalin®) at least twice a
day, 20 - 60 mg of sustained-release methylphenidate (Ritalin-SR®) per day, or a
combination of immediate-release and sustained-release methylphenidate up to a daily
dose not exceeding 60 mg
- having used methylphenidate for at least 3 months at some time in the past and have
been on the same dose for the previous 4-week period without any significant adverse
experiences, considered to be positive responders to methylphenidate therapy, and
agreeing to take only the supplied study drug as treatment for ADHD during the
three-week treatment phase of the study
- able to comply with the study visit schedule and whose parent(s) and teacher are
willing and able to complete the protocol-specified assessments, including behavior
modification procedures
- agreeing not to ingest any caffeine containing beverages (e. g., coffee or soda) or
foods (e. g., chocolate) on days 7, 14, and 21 of the study
Exclusion Criteria:
- Patients having clinically significant gastrointestinal problems, including narrowing
of the gastrointestinal tract
- considered markedly anxious, tense, agitated, or depressed, having psychotic
disorders, a history of seizures, or having a diagnosis of Tourette's syndrome
- whose primary treatment focus is oppositional-defiant disorder, conduct disorder, or
tics, or whose primary treatment focus is other psychiatric conditions such as
depressive disorders, bipolar disorders, or other mood disorders
- having a mean of two blood pressure measurements (systolic or diastolic) equal to or
greater than the 95th percentile for age, sex, and height
- if female, have begun menstruation
Locations and Contacts
Additional Information
Starting date: March 1998
Last updated: June 9, 2011
|